Pioneering Regenerative Medicine
Without Immunosuppression

We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.

Pioneering Regenerative Medicine
Without Immunosuppression

We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.

iTOL-100:

Biotechnology-Derived Protein Inducing
Immune Tolerance Platform

iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.

iTOL-100:

Biotechnology-Derived Protein Inducing
Immune Tolerance Platform

iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic hydrogel microparticle (microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.

Developing a Potential Cure for Type 1 Diabetes

Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes. Using our proprietary biotechnology-derived protein therapy platform, iTOL-100, allogenic pancreatic islets are co-implanted and in preclinical studies have shown immune acceptance and long-term function of the graft with control of blood glucose levels and restoration of insulin secretion. Our follow-on candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islet organoids which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.

Development Pipeline

Email Alerts:

Have the latest news and information delivered directly to your inbox

Get in Touch with us:

Please reach out with any questions

News:

iTolerance, Inc. to Present at Virtual Investor Roundtable Event

Live moderated video webcast discussion among members of management and Key Opinion Leaders, Andrés García, PhD, Haval Shirwan, PhD, and Gary Hall, Jr. on Wednesday, November 17th at 3:00 PM ETMIAMI, FL / November 12, 2021 / iTolerance, Inc....

Email Alerts:

Have the latest news and information delivered directly to your inbox

Get in Touch with us:

Please reach out with any questions

News:

iTolerance, Inc. to Present at Virtual Investor Roundtable Event

Live moderated video webcast discussion among members of management and Key Opinion Leaders, Andrés García, PhD, Haval Shirwan, PhD, and Gary Hall, Jr. on Wednesday, November 17th at 3:00 PM ETMIAMI, FL / November 12, 2021 / iTolerance, Inc....